Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy

Seminars in Radiation Oncology

Volumn 13, Issue 1, 2003, Pages 53-61

  Siemann, Dietmar W ^a,b   Shi, Wenyin ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; COMBRESTATIN A4 DISODIUM PHOSPHATE; COMPLEMENTARY DNA; FUMAGILLOL CHLOROACETYLCARBAMATE; MATRIX METALLOPROTEINASE INHIBITOR; MITOFLAXONE; N ACETYLCOLCHINOL PHOSPHATE; THALIDOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DAMAGE; CELL DEATH; CLINICAL TRIAL; ENDOTHELIUM CELL; HUMAN; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 0037267544     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2003.50005     Document Type: Review

References (105)

1. Tobias J: Clinical practice of radiotherapy. Lancet 339: 159-164, 1992
2. DeVita VT, Hellman S, Rosenberg S: Cancer: Principles and practice of oncology. Philadelphia, Lippincott-Raven, 1997
3. Ausprunk D, Folkman J: Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14:53-65, 1977
4. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 46:467-473, 1986
5. Hahnfeldt P, Panigrahy D, Folkman J, et al: Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 59:4770-4775, 1999
6. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31, 1995
7. Risau W: Mechanisms of angiogenesis. Nature 386:671-674, 1997
8. Siemeister G, Martiny-Baron G, Marme D: The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities. Cancer Metastasis Rev 17:241-248, 1998
9. Tannock IF: Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res 30:2470-2477, 1970
10. van Hinsbergh VW, Collen A, Koolwijk P: Angiogenesis and anti-angiogenesis: Perspectives for the treatment of solid tumors. Ann Oncol 4:60-63, 1999 (Suppl)
11. Molema G, Meijer DK, de Leij LF: Tumor vasculature targeted therapies: Getting the players organized. Biochem Pharmacol 55:1939-1945, 1998
12. Less JR, Skalak TC, Sevick EM, Jain RK: Microvascular architecture in a mammary carcinoma: Branching patterns and vessel dimensions. Cancer Res 51:265-273, 1991
13. Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 49:6449-6465, 1989
14. Vaupel P, Thews O, Hoeckel M: Tumor oxygenation: characterization and clinical implications, in Smyth JF, Boogaerts MA, Ehmer BR (eds): rhErythropoietin in cancer supportive treatment. 1996, pp 205-239
15. Stavri GT, Hong Y, Zachary IC, et al: Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett 358: 311-315, 1995
16. Namiki A, Brogi E, Kearney M, et al: Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 270:31189-31195, 1995
17. Waleh NS, Brody MD, Knapp MA, et al: Mapping of the vascular endothelial growth factor-producing hypoxic cells in multicellular tumor spheroids using a hypoxiaspecific marker. Cancer Res 55:6222-6226, 1995
18. Mazure NM, Chen EY, Yeh P, et al: Oncogenic tranformation an hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 56:3436-3440, 1996
19. Chiarotto JA, Hill RP: A quantitative analysis of the reduction in oxygen levels required to induce up-regulation of vascular endothelial growth factor (VEGF) mRNA in cervical cancer cell lines. Br J Cancer 80:1518-1524, 1999
20. Folkman J: Tumor angiogenesis. Adv Cancer Res 43: 175-203, 1985
21. Moses MA, Langer R: Inhibitors of angiogenesis. Biotech 9:630-634, 1991
22. Schweigerer L: Antiangiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med 73:497-508, 1995
23. Scott P, Harris AL: Current approaches to targeting cancer using antiangiogenesis therapies. Cancer Treat Rev 20:393-412, 1994
24. Fan TP, Jaggar R, Bicknell R: Controlling the vasculature: Angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharm Sci 16:57-66, 1995
25. Kerbel RS: Tumor angiogenesis: Past, present and the near future. Carcinogenesis 21:505-515, 2000
26. Warren RS, Yuan H, Matli MR, et al: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95:1789-1797, 1995
27. Kandel J, Bossy-Wetzel E, Radvanyi F, et al: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66:1095-1104, 1991
28. Benjamin LE, Golijanin D, Itin A, et al: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159-165, 1999
29. Gorski DH, Beckett MA, Jaskowiak NT, et al: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374-3378, 1999
30. Strawn LM, McMahon G, App H, et al: Flk-1 as a target for tumor growth inhibition. Cancer Res 56:3540-3545, 1996
31. Witte L, Hicklin DJ, Zhu Z, et al: Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an antiangiogenic therapeutic strategy. Cancer Metastasis Rev 17:155-161, 1998
32. Klohs WD, Hamby JM: Antiangiogenic agents. Curr Opin Biotechnol 10:544-549, 1999
33. Wedge SR, Ogilvie DJ, Dukes M, et al: ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 60:970-975, 2000
34. Nguyen JT, Wu P, Clouse ME, et al: Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res 58:5673-5677, 1998
35. Shi W, Siemann DW: Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor. Br J Cancer 87:119-126, 2002
36. Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med 49:407-424, 1998
37. O'Reilly MS, Holmgren L, Chen C, et al: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689-692, 1996
38. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997
39. Shi W, Teschendorf C, Muzyczka N, et al: Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Therapy 9:513-521, 2002
40. Little RF, Wyvill KM, Pluda JM, et al: Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 18:2593-2602, 2000
41. Figg WD, Dahut W, Duray P, et al: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7:1888-1893, 2001
42. Denekamp J: Vasculature as a target for tumour therapy. Prog Appl Microcirc 4:28-38, 1984
43. Denekamp J: Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66:181-196, 1993
44. Cliffe S, Taylor ML, Rutland M, et al: Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys 29:373-377, 1994
45. Rewcastle GW, Atwell GJ, Li ZA, et al: Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34:217-222, 1991
46. Ching LM, Joseph WR, Baguley BC: Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br J Cancer 66:128-130, 1992
47. Laws AL, Matthew AM, Double JA, et al: Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 71:1204-1209, 1995
48. Ching LM, Joseph WR, Crosier KE, et al: Induction of tumor necrosis factor a messenger RNA in human and murine cells by the flavone acetic analogue 5,6, dimethylxanthenone-4-acetic acid (NSC64088). Cancer Res 54: 870-872, 1994
49. Philpott M, Baguley BC, Ching LM: Induction of tumour necrosis factor a by single and repeated doses of the antitumor agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36:143-148, 1995
50. Zwi LJ, Baguley BC, Gavin JB, et al: Necrosis in nontumour tissues caused by flavone acetic acid and 5,6-dimethly xanthenone acetic acid. Brit J Cancer 62:932-934, 1990
51. Wilson WR, Li AE, Cowan DS, et al: Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 42:905-908, 1998
52. Siemann DW, Mercer E, Lepler SE, et al: Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99:1-6, 2002
53. Dark GG, Hill SA, Prise VE, et al: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:1829-1834, 1997
54. Grosios K, Holwell SE, McGown AT, et al: In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81:1318-1327, 1999
55. Li L, Rojiani A, Siemann DW: Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy. Int J Radiat Oncol Biol Phys 42:899-903, 1998
56. Rojiani AM, Li L, Rise L, et al: Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of Aids-associated Kaposi's sarcoma. Acta Oncol 41:98-105, 2002
57. Horsman MR, Ehrnrooth E, Ladekarl M, et al: The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumours. Int J Radiat Oncol Biol Phys 42:895-898, 1998
58. Tozer GM, Prise VE, Wilson J, et al: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res 59: 1626-1634, 1999
59. Hori K, Saito S, Nihei Y, et al: Antitumor effects due to irreversible stoppage of tumor tissue blood flow: Evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 90:1026-1038, 1999
60. Blakey DC, Westwood FR, Walker M, et al: Anti-tumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8:1974-1983, 2002
61. Siemann DW, Rojiani AM: Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53:164-171, 2002
62. Chaplin DJ, Pettit GR, Hill SA: Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res 19:189-195, 1999
63. Galbraith SM, Chaplin DJ, Lee F, et al: Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21:93-102, 2001
64. Kanthou C, Tozer GM: The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99:2060-2069, 2002
65. Siemann DW, Warrington KH, Horsman MR: Targeting tumor blood vessels: An adjuvant strategy for radiation therapy. Radiother Oncol 57:5-12, 2000
66. Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys 5:85-91, 1979
67. Teicher BA, Holden SA, Ara G, et al: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 57:920-925, 1994
68. Lund EL, Bastholm L., Kristjansen PE: Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 6:971-978, 2000
69. Lee CG, Heijn M, di Tomaso E, et al: Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565-5570, 2000
70. Kozin SV, Boucher Y, Hicklin DJ, et al: Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61:39-44, 2001
71. Ning S, Laird D, Cherrington JM, et al: The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 157: 45-51, 2002
72. Hess C, Vuong V, Hegyi I, et al: Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 85:2010-2016, 2001
73. Geng L, Donnelly E, McMahon G, et al: Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61:2413-2419, 2001
74. Gorski DH, Mauceri HJ, Salloum RM, et al: Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 58: 5686-5689, 1998
75. Mauceri HJ, Hanna NN, Beckett MA, et al: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394:287-291, 1998
76. Teicher BA, Holden SA, Dupuis NP, et al: Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat 36:227-236, 1995
77. Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702-6704, 1992
78. Dicker AP, William TL, Grant DS: Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol 24:438-442, 2001
79. Kishi K, Petersen S, Petersen C, et al: Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 60:1326-1331, 2000
80. Milas L, Mason K, Hunter N, et al: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701-708, 2000
81. Huang SM, Harari PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6:2166-2174, 2000
82. Teicher BA, Depuis NP, Kusumoto T, et al: Anti-angiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Invest 269-276, 1995
83. Harris AL, Fox S, Leek R, et al: Breast cancer angiogenesis: Therapy target and prognostic factor. Eur J Cancer 31A:831-832, 1995
84. Strohmeyer D: Pathophysiology of tumor angiogenesis and its relevance in renal cell cancer. Anticancer Res 19:1557-1561, 1999
85. Hansen S, Grabau DA, Sorensen FB, et al: The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 6:139-146, 2000
86. Sternfeld T, Foss HD, Kruschewski M, et al: The prognostic significance of tumor vascularization in patients with localized colorectal cancer. Int J Colorectal Dis 14:272-276, 1999
87. Wakisaka N, Wen QH, Yoshizaki T, et al: Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. Laryngoscope 109:810-814, 1999
88. Xiangming C, Hokita S, Natsugoe S, et al: Angiogenesis as an unfavorable factor related to lymph node metastasis in early gastric cancer. Ann Surg Oncol 5:585-589, 1998
89. Ohta Y, Watanabe Y, Murakami S, et al: Vascular endothelial growth factor and lymph node metastasis in primary lung cancer. Br J Cancer 76:1041-1045, 1997
90. Yoon SS, Eto H, Lin CM, et al: Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 59:6251-6256, 1999
91. Zhu Z, Witte L: Inhibition of tumor growth and metastasis by targeting tunnor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs 17:195-212, 1999
92. Wylie S, MacDonald IC, Varghese HJ, et al: The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clin Exp Metastasis 17:111-117, 1999
93. Blezinger P, Wang J, Gondo M, et al: Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 17:343-348, 1999
94. Cao Y, O'Reilly MS, Marshall B, et al: Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 101:1055-1063, 1998
95. Overgaard J, Horsman MR: Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6:10-21, 1996
96. Walenta S, Schroeder T, Mueller-Klieser W: Metabolic mapping with bioluminescence: Basic and clinical relevance. Biomol Eng 18:249-262, 2002
97. Lash CJ, Li AE, Rutland M, et al: Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5- hydroxytryptamine and bioreductive drugs. Br J Cancer 78:439-445, 1998
98. Horsman MR, Murata R, Breidahl T, et al: Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol 476:311-323, 2000
99. Murata R, Overgaard J, Horsman MR: Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 51:1018-1024, 2001
100. Murata R, Siemann DW, Overgaard J, et al: Interaction between combretastatin A4 disodium phosphate and radiation in murine tumours. Radiother Oncol 60:155-161, 2001
101. Murata R, Siemann DW, Overgaard J, et al: Improved tumor response by combining radiation and the vascular damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res 156:503-509, 2001
102. Landuyt W, Ahmed B, Nuyts S, et al: In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 49:443-450, 2001
103. Lozonschi L, Sunamura M, Kobari M, et al: Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 59:1252-1258, 1999
104. O'Reilly MS, Holmgren L, Shing Y, et al: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328, 1994
105. Wedge SR, Kendrew J, Ogilvie DJ, et al: Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular-targeting agent ZD6126 produces an enhanced anti-tumor response. Proc Am Assoc Cancer Res 43:1081, 2002 (abstr)